ACRO Comments on Naming of FDA Commissioner and Deputy


John Lewis
[email protected]

ACRO Comments on Naming of FDA Commissioner and Deputy

Date of Release: 16 March 2009

Remarks should be attributed to ACRO Executive Director Doug Peddicord, PhD.

March 16, 2008 – WASHINGTON, DC – Under Peggy Hamburg’s leadership we expect the FDA to refocus on science and research to better ensure the health of all Americans and ACRO is committed to maintaining its active involvement in the Critical Path initiative and other public-private collaborations.

We note that while the stimulus bill provided billions of dollars for important healthcare initiatives like comparative effectiveness research and health information technology, FDA was conspicuously absent from the list of entities that received additional funding in these areas. Given the unique and vital role the FDA plays in our nation’s healthcare system and in the drug development process, ACRO urges the Administration, Congress and incoming HHS Secretary Sebelius to fund the FDA at the level of support required for a modern, world-class regulatory agency.

ACRO salutes the public service of Drs. Hamburg and Sharfstein and we look forward to working with them in their new roles.

About ACRO
The Association of Clinical Research Organizations (ACRO) is the professional organization of companies whose focus is clinical research. The association provides an active voice for the CRO industry, which provides specialized services that are integral to the development of drugs, biologics and medical devices. ACRO helps its members improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 70,000 professionals worldwide. For more information, please visit

Scroll to Top